<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01084499</url>
  </required_header>
  <id_info>
    <org_study_id>YCD143</org_study_id>
    <nct_id>NCT01084499</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Letrozole 2.5 mg Tablets</brief_title>
  <official_title>Bioequivalence Study of YUHAN Letrozole 2.5 mg Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bioequivalence
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study was to determine the bioequivalence of letrozole 2.5 mg tablets
      after administration of single doses to normal healthy Korean subjects under fasted
      conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Letrozole : AUC0-tz</measure>
    <time_frame>Predose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 96, 168, 312 hrs after drug administration</time_frame>
    <description>Area Under the Concentration-time Curve of Letrozole in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Letrozole : Cmax</measure>
    <time_frame>Predose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 96, 168, 312 hrs after drug administration</time_frame>
    <description>Maximum Measured Concentration of Letrozole in Plasma</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Femara First, Then Peratra (Sequence 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first receives a branded letrozole (reference - Femara), then a generic letrozole (test - Peratra). Each treatment period is separated by a 5-week washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peratra First, Then Femara (Sequence 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first receives a generic letrozole (test - Peratra) , then a branded letrozole (reference - Femara). Each treatment period is separated by a 5-week washout period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Femara (Sequence 1)</intervention_name>
    <description>Participant who is assigned to the Sequence 1 first receive Femara, then a Peratra. Each treatment period is separated by a 5-week washout period.</description>
    <arm_group_label>Femara First, Then Peratra (Sequence 1)</arm_group_label>
    <other_name>Femara Tab.[Letrozole 2.5mg]</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peratra (Sequence 1)</intervention_name>
    <description>Participant who is assigned to the Sequence 1 first receive Femara, then a Peratra. Each treatment period is separated by a 5-week washout period.</description>
    <arm_group_label>Femara First, Then Peratra (Sequence 1)</arm_group_label>
    <other_name>Peratra Tab.[Letrozole 2.5mg]</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Femara (Sequence 2)</intervention_name>
    <description>Participant who is assigned to the Sequence 2 first receive Peratra, then a Femara. Each treatment period is separated by a 5-week washout period.</description>
    <arm_group_label>Peratra First, Then Femara (Sequence 2)</arm_group_label>
    <other_name>Femara Tab.[Letrozole 2.5mg]</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peratra (Sequence 2)</intervention_name>
    <description>Participant who is assigned to the Sequence 2 first receive Peratra, then a Femara. Each treatment period is separated by a 5-week washout period.</description>
    <arm_group_label>Peratra First, Then Femara (Sequence 2)</arm_group_label>
    <other_name>Peratra Tab.[Letrozole 2.5mg]</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers in the age between 19 to 55 years old

          -  Subjects were neither congenital nor chronic diseases.

          -  Subjects were selected after passing a clinical screening procedure that included a
             physical examination and laboratory tests.

          -  Availability of subject for the entire study period and willingness to adhere to
             protocol requirements, as evidenced by a signed Informed Consent Form.

        Exclusion Criteria:

          -  Any history of a clinical condition which might affect drug absorption, distribution,
             metabolism or excretion or might be risk factors, e.g. clinically significant disorder
             in heart, liver, respiratory system, liver, kidney, gastrointestinal system and CNS

          -  Had a history of myocardial infarction, stroke, hypertension, arrhythmia, coronary
             artery disease, disease of neuropsychiatry, gastrointestinal system surgery (excluding
             appendectomy, herniotomy)

          -  Current clinically significant disorder in history taking or physical examination

          -  Acute disease within 14 days preceding the first application of study medication

          -  Had an relevant allergic disease

          -  Had history of hypersensitivity to drugs or any food

          -  Positive for Hepatitis B antigen, Hepatitis C antibody, HIV antibody, or High Quality
             Syphilis Reagin Test

          -  Excessive caffeine, alcohol intake and smoker(caffeine&gt;5 units/day, alcohol&gt;3
             units/day(1 unit = pure alcohol 10ml), cigarettes&gt; 20 cigarettes /day)

          -  Subjects who excessive alcohol intake or drug which affect drug metabolism enzyme
             intake within 30 days preceding study

          -  History of drug abuse or positive for urinary testing of drugs abuse (amphetamine,
             barbiturates, cocaine, opioids, benzodiazepines etc.)

          -  Has donated whole blood within 60days or apheresis within 14days preceding the first
             application of study medication

          -  Received other investigational drug within 60days preceding the first application of
             study medication

          -  Taken any herbal medicine within 30days, prescription medication within 14 days or
             over-the-counter drug (except for vitamins, minerals) within 10days preceding the
             first application of study medication (might affect this study or safety of subjects
             as judged by the investigator)

          -  Subjects couldn't eat ASAN MEDICAL CENTER standard meal or were unsuitable for this
             study as judged by investigators
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyeong-seok Lim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 9, 2010</study_first_submitted>
  <study_first_submitted_qc>March 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2010</study_first_posted>
  <results_first_submitted>February 14, 2019</results_first_submitted>
  <results_first_submitted_qc>March 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 29, 2019</results_first_posted>
  <last_update_submitted>March 26, 2019</last_update_submitted>
  <last_update_submitted_qc>March 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study period: Jan 2009 ~ May 2009</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Femara First, Then Peratra (Sequence 1)</title>
          <description>Participants first received a branded letrozole (reference - Femara), then a generic letrozole (test - Peratra). Each treatment period was separated by a 5-week washout period.</description>
        </group>
        <group group_id="P2">
          <title>Peratra First, Then Femara (Sequence 2)</title>
          <description>Participants first received a generic letrozole (test - Peratra), then branded letrozole (reference - Femara). Each treatment period was separated by a 5-week washout period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13">First Intervention (Sequence 1) : Femara (1 Day)</participants>
                <participants group_id="P2" count="13">First Intervention (Sequence 2) : Peratra (1 Day)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Washout (5 Weeks)</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13">Second Intervention (Sequence 1) : Peratra (1 Day)</participants>
                <participants group_id="P2" count="13">Second Intervention (Sequence 2) : Femara (1 Day)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Femara First, Then Peratra (Sequence 1)</title>
          <description>Participants first received a branded letrozole (reference - Femara), then a generic letrozole (test - Peratra). Each treatment period was separated by a 5-week washout period.</description>
        </group>
        <group group_id="B2">
          <title>Peratra First, Then Femara (Sequence 2)</title>
          <description>Participants first received a generic letrozole (test - Peratra), then a branded letrozole (reference - Femara). Each treatment period was separated by a 5-week washout period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.8" spread="4.8"/>
                    <measurement group_id="B2" value="27.5" spread="4.1"/>
                    <measurement group_id="B3" value="28.1" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Letrozole : AUC0-tz</title>
        <description>Area Under the Concentration-time Curve of Letrozole in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point.</description>
        <time_frame>Predose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 96, 168, 312 hrs after drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peratra</title>
            <description>The group of participants who were administered Peratra.</description>
          </group>
          <group group_id="O2">
            <title>Femara</title>
            <description>The group of participants who were administered Femara.</description>
          </group>
        </group_list>
        <measure>
          <title>Letrozole : AUC0-tz</title>
          <description>Area Under the Concentration-time Curve of Letrozole in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point.</description>
          <units>ngâ€¢hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2074.71" spread="826.15"/>
                    <measurement group_id="O2" value="2094.63" spread="870.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Letrozole : Cmax</title>
        <description>Maximum Measured Concentration of Letrozole in Plasma</description>
        <time_frame>Predose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 96, 168, 312 hrs after drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peratra</title>
            <description>The group of participants who were administered Peratra.</description>
          </group>
          <group group_id="O2">
            <title>Femara</title>
            <description>The group of participants who were administered Femara.</description>
          </group>
        </group_list>
        <measure>
          <title>Letrozole : Cmax</title>
          <description>Maximum Measured Concentration of Letrozole in Plasma</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.38" spread="6.66"/>
                    <measurement group_id="O2" value="38.13" spread="7.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 Weeks (1) First Intervention : 2 Weeks (Blood samples were obtained before dosing and at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 96, 168, and 312 hours after oral administration of 2.5 mg of letrozole) (2) Washout : 5 Weeks (3) Second Intervention : 2 Weeks (4) Last safety profile assessment : 1 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Peratra</title>
          <description>The group of participants who were administered Peratra.</description>
        </group>
        <group group_id="E2">
          <title>Femara</title>
          <description>The group of participants who were administered Femara.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Bilirubin Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Blood Triglyceride Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Creatine Kinase Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Blood Lactate Dehydrogenase Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Blood Calcium Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Urinary Occult Blood Positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ankle sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The results of the study shall be owned by the Sponsor. The results of this study can be published in journals with the consent of the Sponsor, and the Sponsor can also request the presentation of the results to the investigator(s).</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Principal Investigator</name_or_title>
      <organization>Asan Medical Center</organization>
      <email>mdlhs@amc.seoul.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

